Leidos Reports Strong Third Quarter 2024 Results and Raises Full-Year Guidance

On October 29, 2024 Leidos Holdings, Inc. (NYSE: LDOS) reported financial results for the third quarter of fiscal year 2024 (Press release, Leidos, OCT 29, 2024, View Source [SID1234649390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Continued improvement in operating performance across all segments drove excellent revenue growth, record margins for net income and adjusted EBITDA, substantial earnings growth, strong cash flow, and robust bookings," said Leidos Chief Executive Officer Tom Bell. "These results demonstrate clearly how our collaborative and innovative workforce is focused on consistent execution for our customers and shareholders. With a healthy balance sheet, improving business development performance, and emerging ‘North Star’ strategy, Leidos is well positioned to deliver robust and sustainable returns as we move forward."

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

On October 29, 2024 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, reported that the Company will present at two upcoming scientific conferences (Press release, Sensei Biotherapeutics, OCT 29, 2024, View Source [SID1234647496]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference and Presentation Details:

PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain

Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody
Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer
Session: Antibody-Based Cancer Therapies
Date and time: Tuesday, November 5, 2024, 9:00 a.m. CET (Central European Time)

Society for Immunotherapy Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting, November 6-10, Houston Texas

Title: Spatial proteomic profiling of VISTA and PSGL-1 interactions across cancer indications
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Presentation Type: Poster
Abstract Number: 70
Date and Time: Saturday, November 9, 2024, 12:15–1:45 p.m. & 7:00-8:30 p.m. CST.
Location: Level 1-Exhibit Halls AB (George R. Brown Convention Center)

Alligator Bioscience and Aptevo Therapeutics to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024

On October 29, 2024 Alligator Bioscience AB ("Alligator") (ATORX) and Aptevo Therapeutics ("Aptevo") (Nasdaq: APVO) reported that new, positive interim data from the dose escalation phase of their Phase 1 trial evaluating ALG.APV-527 will be presented in a poster session on Friday, November 8, 2024, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2024 (SITC) (Free SITC Whitepaper), taking place November 6th – 10th, 2024 in Houston, Texas (Press release, Alligator Bioscience, OCT 29, 2024, View Source [SID1234647474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Poster number: #673
Title: Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4×4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity
Presenter: Thomas Marron, MD, PhD
Date/Time: Friday, November 8th from 12:15-1:45 and 5:30-7:00 PM US Central time.

About the Trial
The ALG.APV-527 Phase 1 trial is a multi-center, multi-cohort, open-label dose-escalation trial that will include administration of ALG.APV-527 up to six escalating dose levels in a 3+3 design*. The trial is enrolling adult patients with multiple solid tumor types/histologies likely to express the 5T4 antigen. ALG.APV-527 will be given intravenously once every two weeks. The trial will assess the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of ALG.APV-527.

*The 3+3 design proceeds in cohorts of three patients treated at increasing dose levels. Dose escalation stops when at least two out of three or six patients experience dose limiting toxicities (DLTs) at that dose level.

About ALG.APV-527
ALG.APV-527 is a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4. This has the potential to be clinically important because 4-1BB can stimulate the immune cells (antitumor-specific T cells and NK cells) involved in tumor control, making 4-1BB a particularly compelling target for cancer immunotherapy. 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors including non-small-cell lung carcinoma (NSCLC), breast, head and neck, cervical, renal, gastric, and colorectal cancer.

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

On October 29, 2024 Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, reported that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO (methotrexate) to include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA) (Press release, Shorla Oncology, OCT 29, 2024, View Source [SID1234647498]). With this approval, JYLAMVO is currently the only oral liquid methotrexate on the market approved for both adult and pediatric indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For patients with chronic conditions including cancer, JYLAMVO offers a convenient, palatable option for patients who may have difficulty swallowing pills"

"This approval follows JYLAMVO’s successful use in adult patients and represents a critical step forward in addressing the unmet needs of pediatric care in oncology and autoimmune diseases," said Sharon Cunningham, chief executive officer of Shorla Oncology. "We are pleased to offer a convenient, patient-friendly alternative for both adult and pediatric patients in the U.S. as we continue to develop innovative solutions for those with limited treatment options."

JYLAMVO was first approved by the FDA as the only oral liquid methotrexate to treat adults with acute lymphoblastic leukemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis and severe psoriasis.

JYLAMVO has an orange flavor and comes with a dedicated dosing syringe.

"For patients with chronic conditions including cancer, JYLAMVO offers a convenient, palatable option for patients who may have difficulty swallowing pills," said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology. "At Shorla, we are committed to continuity of supply of age-appropriate formulations for patients in need."

Rayna Herman, chief commercial officer of Shorla Oncology added, "In addition to its palatable formulation, JYLAMVO offers key differences over similar drugs, such as room temperature stability for three months after opening, which eliminates the need for refrigeration before dispensing and adds convenience for patients. We are excited to expand our portfolio of innovative therapies for underserved patient populations."

About JYLAMVO

JYLAMVO is an anti-inflammatory and cancer oral methotrexate solution approved by the U.S. Food and Drug Administration for use in adult and pediatric patients with rheumatological, dermatological and oncological diseases. JYLAMVO is an easy-to-administer, orange flavored solution that eliminates the need for crushing or splitting pills, or compounding into a liquid formulation. JYLAMVO offers advantages because it remains stable at room temperature (68°F to 77°F) for 90 days and does not require cold chain storage pre-dispense.

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

On October 29, 2024 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, reported highly promising early data from a preclinical study of its latest cancer treatment (Press release, Hoth Therapeutics, OCT 29, 2024, View Source [SID1234647497]). The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and took place under a sponsored scientific research agreement with NC State University.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study measured tumor volumes in treated and untreated subjects over the course of the experiment. Tumor volume measurements in the treated group exhibited minimal changes, suggesting that the treatment effectively inhibited tumor growth. Additionally, all tumors in the treated animals displayed remarkable consistency in volume, with standard deviation error bars barely visible—a strong indication of the treatment’s uniformity and reproducibility in suppressing tumor growth.

"These early findings are incredibly encouraging and demonstrate that our treatment has the potential to halt tumor progression consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The stability and low variability observed in tumor volumes among treated animals are indicative of a promising therapeutic effect, and we’re excited to move forward with further testing as we process additional tissue data."

Key observations from the initial data include:

Stabilized Tumor Growth: Tumor volumes in treated subjects remained remarkably stable over the course of the study, suggesting that the treatment may significantly inhibit tumor growth.

Consistency Across Subjects: Tumor sizes were highly consistent across all treated animals, as demonstrated by the minimal error bars on the graph. This uniform response highlights the treatment’s potential reproducibility and reliability.

Comparison with Untreated Controls: In contrast, untreated subjects showed greater variability and an increase in tumor volume, underscoring the potential efficacy of the treatment in slowing or halting tumor growth.
As Hoth Therapeutics advances this research, the company will continue analyzing additional tissue data to further validate these results. The company is committed to moving forward with the development of this promising treatment and exploring its full potential for patients in need of effective cancer therapies.